BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

CVR boosts Ambit in Daiichi Sankyo deal

Daiichi Sankyo Co. Ltd. (Tokyo:4568) will acquire Ambit Biosciences Corp. (NASDAQ:AMBI) for up to $410 million. The deal includes $315 million in upfront cash, or $15 per share, plus $95 million in commercial milestones in the form of a contingent value right (CVR) worth up to $4.50 per share. more >>

   COMPANY NEWS

AMAG gains on M&A deal to add Makena

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) jumped $6.54 (28%) to $29.72 Monday on news it agreed to acquire the maternal health business of Lumara Health Inc. (Chesterfield, Mo.) -- once known as KV Pharmaceutical Co. -- for $675 million in cash and stock, plus $350 million in potential sales milestones. AMAG will gain ownership of Lumara's Makena hydroxyprogesterone caproate injection to prevent preterm birth. more >>

EMA validates Opdivo MAA

Bristol-Myers Squibb Co. (NYSE:BMY) said EMA validated an MAA for Opdivo nivolumab to treat non-small cell lung cancer (NSCLC). The pharma said the application is the "first completed regulatory submission" for a PD-1 inhibitor in that tumor type. more >>

Alimera gains on Iluvien approval

Alimera Sciences Inc. (NASDAQ:ALIM) added $0.41 to $5.33 on Monday after FDA approved Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema in patients who have been previously treated with corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). more >>

   CLINICAL NEWS

Genentech unveils OS benefit for Perjeta combo

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) presented Phase III data showing that Perjeta pertuzumab in combination with Herceptin trastuzumab and docetaxel chemotherapy increased the overall survival (OS) of patients with previously untreated HER2-positive metastatic breast cancer (MBC) by 15.7 months compared to Herceptin plus chemotherapy. more >>

PARP ovarian data boosts Clovis

Clovis Oncology Inc. (NASDAQ:CLVS) gained $5.59 (13%) to $48.08 on Monday after presenting results from two trials evaluating rucaparib (CO-338) for platinum-sensitive ovarian cancer at the European Society of Medical Oncology (ESMO) Congress in Madrid. more >>

Seattle Genetics: More Adcetris data at ASH

Seattle Genetics Inc. (NASDAQ:SGEN) was off $2.98 to $38.30 on Monday after reporting Adcetris brentuximab vedotin met the primary endpoint of improving progression-free survival (PFS) vs. placebo (HR=0.57, p=0.001) in the Phase III AETHERA trial to treat patients with Hodgkin's lymphoma (HL) who are at risk of progression following an autologous stem cell transplant (ASCT). The company said the data equate to a 75% gain in PFS for the treated arm. more >>

Tonix plummets on Phase IIb miss

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell $7.01 (50%) to $6.95 on Monday after its TNX-102 SL missed the primary endpoint in a Phase IIb trial to treat fibromyalgia. more >>

Catalyst's Firdapse meets in LEMS Phase III

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) said its oral potassium channel blocker Firdapse amifampridine met the co-primary endpoints in a Phase III trial to treat Lambert-Eaton myasthenic syndrome (LEMS). In the 38-patient study, Firdapse improved scores vs. placebo on the change in subject global impression and quantitative myasthenia gravis scales (p=0.0028 and p=0.0452, respectively). more >>

   FINANCIAL NEWS

NeuroSigma sets IPO range

NeuroSigma Inc. (Los Angeles, Calif.) amended its IPO on NASDAQ and now plans to sell 3.6 million shares at $13-$15. At $14, NeuroSigma would raise $50 million and be valued at $176.9 million. The company filed last month to raise up to $50 million. Jefferies; BTIG; and Craig-Hallum Capital Group are underwriters. more >>

Advertisement

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS
COVER STORY

Patching compassionate access

Congress is gearing up to reconsider compassionate access to drugs, but wholesale reform looks unlikely.

Targeting PREA

Oncologists and patient advocates want Pediatric Research Equity Act mandates to study new targeted cancer drugs in children.

PRODUCT DISCOVERY & DEVELOPMENT

An arresting development

G1 Therapeutics aims for first-in-class chemoprotectant with CDK4 and CDK6 inhibitor.

EMERGING COMPANY PROFILE

Ossianix: Shark teeth

Ossianix is developing small shark-derived single domain antibodies that could hit targets tough to access with traditional approaches.

Oricula: Preserving hearing

Oricula is developing a small molecule that could prevent hearing loss during aminoglycoside treatment.

REGULATION

Patient factors

A dearth of programs for blood disorder patients with inhibitors will leave a major unmet need until gene therapies come to market.

FINANCE

Adopting Adaptimmune

Why investors preferred Adaptimmune's TCR platform to other T cell therapy cos

CureVac bet paying off

Boehringer cancer vaccine deal shows Hopp's EUR80 million CureVac bet paying off

Avalon-GSK bet on familiarity, speed

How Avalon, GSK chose next newcos for their pre-POC collaboration

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement